Upper gastrointestinal tract immune‐related adverse events: Two cases of obstructive complications occurred in immune consolidation therapy after sequential chimeric antigen receptor T cell therapy with autologous hematopoietic stem cell transplantation for refractory/relapsed diffuse large B cell lymphoma

Documenti analoghi

• Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T‐cell therapy for relapsed and refractory lymphoma
  di: Michael Dickinson, et al.
  Pubblicazione: (2025)
• CD19 chimeric antigen receptor‐T cell therapy in murine immune thrombocytopenia
  di: Fengjiao Han, et al.
  Pubblicazione: (2025)
• Acute kidney injury after chimeric antigen receptor T‐cell therapy is associated with inferior survival in patients with relapsed/refractory large B‐cell lymphoma
  di: John Sharp, et al.
  Pubblicazione: (2025)
• Anti‐CD19 chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study
  di: Aung M. Tun, et al.
  Pubblicazione: (2024)
• Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
  di: Joshua Mehr, et al.
  Pubblicazione: (2024)